American Biogenetic Sciences, Inc. Panel Reviews Antibody Technology at International Meeting of Immunologists

Apr 23, 2001, 01:00 ET from American Biogenetic Sciences, Inc.

    COPIAGUE, N.Y., April 23 /PRNewswire/ -- American Biogenetic Sciences,
 Inc. (ABS) (Nasdaq:   MABA) announced today that Scientists working with ABS
 reported data showing that the company's antigen-free (A-F) mice have a
 significantly stronger immune response to immunization than do germ-free or
 conventional laboratory mice.  Antigen free mice were shown to have a stronger
 T cell response and IgG antibodies in sera were shown to have three fold
 higher average affinity.  This could lead to more efficient production of
 monoclonal antibodies due to a better "sound/noise" ratio, especially
 involving "difficult" antigens, emphasized by Professor Nico Bos of the
 Department of Cell Biology, University of Groningen, The Netherlands.
     The Co-chairman of the Congress, Professor Rem V. Petrov, D.Sc., Vice
 President of the Russian Academy of Sciences, noted, "Over 1,000 scientists
 and theoretical and clinical immunologists from forty-five countries attended
 this international congress.  Some of those present were unaware of ABS'
 antigen-free technology and many remarked on its outstanding potential in the
 field of immunological research and the production of high affinity and very
 specific monoclonal antibodies in particular."
     The findings were reviewed at the VII International Congress on
 Immunorehabilitation, New York City (April 14-17, 2001), as part of a
 roundtable session at which American Biogenetic Sciences and co-investigators
 detailed features of ABS' antigen-free technology and its clinical potential.
 The panel was chaired by Company Chairman and CEO Alfred J. Roach and included
 presentations by:
     --James H. McLinden, Ph.D., Senior Vice President and Chief Scientific
       Officer, ABS
     --Nico Bos, Ph.D., Dept. of Cell Biology, University of Groningen, The
       Netherlands
     --David Carville, Ph.D., Cardiovascular Consultant to ABS
 
     Studies conducted by the Department of Cell Biology at the University of
 Groningen concluded that when research antigens were presented to A-F mice,
 the A-F mice made more antigen-specific antibodies with higher affinity than
 did their germ-free and conventional counterparts.
     Renowned theoretical and clinical scientists who attended the Conference
 included Prof. John W. Hadden, Division of Immunopharmacology, Department of
 Internal Medicine, University of South Florida College of Medicine, Prof.
 Michael Sela, Israel, Past President of International Union of Immunological
 Society, Prof. Alain de Weck, President of the International Association Of
 Allergology And Clinical Immunology (IAACI), Switzerland.
     MH-1, a monoclonal antibody developed with A-F technology, is a sensitive
 marker for a protein whose levels begin to rise just as a blood clot begins
 forming. The panel reviewed data that suggests that MH-1 may have utility as a
 thrombus-seeking drug delivery vehicle for thrombolytics and also anticancer
 agents designed to shrink tumors and prevent them from spreading.
     The antithrombotic utility of this agent for the inhibition/prevention of
 restenosis following coronary intervention was also discussed. Data from
 preclinical studies demonstrating this clinical phenomenon were presented.
 
     American Biogenetic Sciences, Inc., based in Copiague, N.Y., researches
 and develops diagnostic tests for cardio-pulmonary conditions and infectious
 diseases, as well as for new treatments for neurological disorders including
 epilepsy, migraine, mania, Parkinson's disease and Alzheimer's disease.
 
     Statements in this press release that are not strictly historical are
 "forward looking" statements within the meaning of the Private Securities
 Litigation Reform Act of 1995, and should be considered as subject to various
 risks and uncertainties that could cause actual results to differ materially
 from those anticipated, including the risk that its products may not be
 commercialized. For further details and a discussion of these risks and
 uncertainties, see the Company's Securities and Exchange Commission filings
 including its annual report on Form 10-K.
 
     For a complete analysis of the ABS' pipeline go to:
 http://www.mabxa.com/research.html.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X48347427
 
 

SOURCE American Biogenetic Sciences, Inc.
    COPIAGUE, N.Y., April 23 /PRNewswire/ -- American Biogenetic Sciences,
 Inc. (ABS) (Nasdaq:   MABA) announced today that Scientists working with ABS
 reported data showing that the company's antigen-free (A-F) mice have a
 significantly stronger immune response to immunization than do germ-free or
 conventional laboratory mice.  Antigen free mice were shown to have a stronger
 T cell response and IgG antibodies in sera were shown to have three fold
 higher average affinity.  This could lead to more efficient production of
 monoclonal antibodies due to a better "sound/noise" ratio, especially
 involving "difficult" antigens, emphasized by Professor Nico Bos of the
 Department of Cell Biology, University of Groningen, The Netherlands.
     The Co-chairman of the Congress, Professor Rem V. Petrov, D.Sc., Vice
 President of the Russian Academy of Sciences, noted, "Over 1,000 scientists
 and theoretical and clinical immunologists from forty-five countries attended
 this international congress.  Some of those present were unaware of ABS'
 antigen-free technology and many remarked on its outstanding potential in the
 field of immunological research and the production of high affinity and very
 specific monoclonal antibodies in particular."
     The findings were reviewed at the VII International Congress on
 Immunorehabilitation, New York City (April 14-17, 2001), as part of a
 roundtable session at which American Biogenetic Sciences and co-investigators
 detailed features of ABS' antigen-free technology and its clinical potential.
 The panel was chaired by Company Chairman and CEO Alfred J. Roach and included
 presentations by:
     --James H. McLinden, Ph.D., Senior Vice President and Chief Scientific
       Officer, ABS
     --Nico Bos, Ph.D., Dept. of Cell Biology, University of Groningen, The
       Netherlands
     --David Carville, Ph.D., Cardiovascular Consultant to ABS
 
     Studies conducted by the Department of Cell Biology at the University of
 Groningen concluded that when research antigens were presented to A-F mice,
 the A-F mice made more antigen-specific antibodies with higher affinity than
 did their germ-free and conventional counterparts.
     Renowned theoretical and clinical scientists who attended the Conference
 included Prof. John W. Hadden, Division of Immunopharmacology, Department of
 Internal Medicine, University of South Florida College of Medicine, Prof.
 Michael Sela, Israel, Past President of International Union of Immunological
 Society, Prof. Alain de Weck, President of the International Association Of
 Allergology And Clinical Immunology (IAACI), Switzerland.
     MH-1, a monoclonal antibody developed with A-F technology, is a sensitive
 marker for a protein whose levels begin to rise just as a blood clot begins
 forming. The panel reviewed data that suggests that MH-1 may have utility as a
 thrombus-seeking drug delivery vehicle for thrombolytics and also anticancer
 agents designed to shrink tumors and prevent them from spreading.
     The antithrombotic utility of this agent for the inhibition/prevention of
 restenosis following coronary intervention was also discussed. Data from
 preclinical studies demonstrating this clinical phenomenon were presented.
 
     American Biogenetic Sciences, Inc., based in Copiague, N.Y., researches
 and develops diagnostic tests for cardio-pulmonary conditions and infectious
 diseases, as well as for new treatments for neurological disorders including
 epilepsy, migraine, mania, Parkinson's disease and Alzheimer's disease.
 
     Statements in this press release that are not strictly historical are
 "forward looking" statements within the meaning of the Private Securities
 Litigation Reform Act of 1995, and should be considered as subject to various
 risks and uncertainties that could cause actual results to differ materially
 from those anticipated, including the risk that its products may not be
 commercialized. For further details and a discussion of these risks and
 uncertainties, see the Company's Securities and Exchange Commission filings
 including its annual report on Form 10-K.
 
     For a complete analysis of the ABS' pipeline go to:
 http://www.mabxa.com/research.html.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X48347427
 
 SOURCE  American Biogenetic Sciences, Inc.

RELATED LINKS

http://MABXA.com